NIH · GLP-1 Program Management
NIH manages all GLP-1 access and cost.
Who qualifies, which products are covered, how members stay on track and what every fill costs, managed in one place.
GLP-1 medications are now one of the fastest-growing lines in plan pharmacy spend. National Integrative Health (NIH) helps the plan control both sides of that cost: access and price. NIH builds and enforces the plan’s rules for who qualifies, keeps members on the preferred product at the matched dose, monitors every refill, and locks in a fixed, all-in price per fill, so GLP-1 spend stays predictable.
How NIH manages GLP-1 access and cost
Formulary design
Single-manufacturer or multi-product formulary. The preferred product for each ingredient, at the matched dose. Step therapy and prior authorization rules aligned to the plan’s criteria. Plan design and SPD language to support the program.
Eligibility management
Plan-set clinical criteria for initial approval and continuation. NIH documents and enforces the criteria, coordinates with prescribers and the plan’s clinicians, and activates only approved members.
Engagement management
One NIH Patient Advocate for each member. One-month fills and refill monitoring, because dosing changes often. Continuation reviews and no-fill cutoffs keep the program focused.
Pricing and reporting
Commercial-direct GLP-1 pricing through NIH’s national GLP-1 partnership. A fixed, all-in price per 30-day fill with no rebate dependency. Utilization, cost and outcome reporting for the plan.
Why fixed pricing matters
Under a rebate-based model, tighter eligibility criteria can raise the unit cost, because fewer fills qualify for rebates. NIH’s price is fixed per fill, so the plan’s clinical rules and its cost move in the same direction.
Design options
- Coverage criteria
- Set by the plan, narrow or broad
- Member cost share
- Optional flat monthly contribution
- Telehealth
- Optional, for the whole group
- Fulfillment
- Retail pickup or home delivery, by product
How it runs
- 1 Design
- 2 Review
- 3 Activate
- 4 Manage
Modeled
At scale (modeled)
- Cost per utilizer versus standard estimate
- 36%
- lower cost per utilizer than the incumbent carrier’s standard estimate
- Versus risk-managed estimate
- 57%
- lower than its risk-managed estimate
- Projected annual savings
- $11.5–$25.8M
- projected annual savings at full take-up
Fits the rest of your NIH program
- Inside an MSO Plan Audit
- As a stand-alone program
- Funded by specialty and infusion savings
